Zoetis Inc.
ZTSFull coverage—Zoetis Inc.
ZTSNew York Stock ExchangeFull coverage
Q3 fiscal 2026 edition
A free account unlocks one dossier edition a month.
Create a free accountAlready have an account? Sign in
Summary
Free to read
Zoetis is the largest animal-health company by revenue, selling prescription medicines, vaccines and diagnostics for pets and farm animals, mostly through veterinarians. Its core pet franchises are losing price and share for the first time: in the third quarter of 2026 dermatology revenue fell 15.7% as cheaper rival drugs arrived, US companion-animal revenue fell 8%, and adjusted EPS rose only because the share count was 7.1% lower. Livestock and diagnostics are still growing, and management expects US approval of long-acting Cytopoint and Simparica Duo by the end of 2026, but says it will not plan for any improvement in competition in 2027. Moatsight estimates revenue of about $9.2 billion and free cash flow of about $2.25 billion over the next four quarters.
In the full dossier
- Part 1In brief
- Part 2Business explainer
- Part 3Earnings
- Part 4Valuation and projections
- Part 5What changed
General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers